Summary
5.04
0.13
(2.55%)
04/13/2026
Abeona Therapeutics Inc. (ABEO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 2.55 | 3.15 | -4.47 | -3.73 | -8.40 | 17.46 | -87.33 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | A- |
| Recommended Rating | Buy |
| DCF | Neutral |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Sell |
| P/E | Neutral |
| P/B | Neutral |
Earnings
| Trading Data | ||
| Close | 5.04 | |
| Open | 4.89 | |
| High | 5.09 | |
| Low | 4.89 | |
| Volume | 562,771 | |
| Change | 0.13 | |
| Change % | 2.55 | |
| Avg Volume (20 Days) | 1,525,434 | |
| Volume/Avg Volume (20 Days) Ratio | 0.37 | |
| 52 Week Range | 4.00 - 7.54 | |
| Price vs 52 Week High | -33.22% | |
| Price vs 52 Week Low | 25.88% | |
| Range | -3.73 | |
| Gap Up/Down | -0.15 | |
Profitibility | ||
| Market Capitalization (Mln) | 213 | |
| Revenue per share | 0.1099 | |
| Net Income per share | 1.3443 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 3.6525 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/07 08:30 EST - globenewswire.com
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr....
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr....
04/06 08:30 EST - globenewswire.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
04/02 08:30 EST - globenewswire.com
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene...
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene...
03/25 01:10 EST - defenseworld.net
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation,...
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation,...
03/19 13:18 EST - seekingalpha.com
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a >$4B cumulative revenue opportunity....
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a >$4B cumulative revenue opportunity....
03/17 15:12 EST - seekingalpha.com
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
03/17 07:30 EST - globenewswire.com
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc....
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc....
03/09 07:30 EST - globenewswire.com
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and...
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and...
03/03 07:30 EST - globenewswire.com
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress.
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress.
02/18 02:09 EST - defenseworld.net
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating...
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating...
01/28 05:32 EST - defenseworld.net
Madhav Vasanthavada Sells 12,610 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock
Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) insider Madhav Vasanthavada sold 12,610 shares of the firm's stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $5.29, for a total value of $66,706.90. Following the completion of the sale, the...
Madhav Vasanthavada Sells 12,610 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock
Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) insider Madhav Vasanthavada sold 12,610 shares of the firm's stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $5.29, for a total value of $66,706.90. Following the completion of the sale, the...
01/24 05:23 EST - defenseworld.net
Vishwas Seshadri Sells 69,832 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock
Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) CEO Vishwas Seshadri sold 69,832 shares of the firm's stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $372,204.56. Following the transaction, the chief...
Vishwas Seshadri Sells 69,832 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock
Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) CEO Vishwas Seshadri sold 69,832 shares of the firm's stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $372,204.56. Following the transaction, the chief...
12/30 03:18 EST - defenseworld.net
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy...
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy...
12/15 07:30 EST - globenewswire.com
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business...
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business...
12/13 03:50 EST - defenseworld.net
AWM Investment Company Inc. Acquires New Shares in Abeona Therapeutics Inc. $ABEO
AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ: ABEO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 470,000 shares of the biopharmaceutical company's stock, valued at approximately $2,670,000....
AWM Investment Company Inc. Acquires New Shares in Abeona Therapeutics Inc. $ABEO
AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ: ABEO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 470,000 shares of the biopharmaceutical company's stock, valued at approximately $2,670,000....
12/11 07:30 EST - globenewswire.com
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel)...
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel)...
12/08 07:30 EST - globenewswire.com
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with...
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with...
Market News
×
Loading news…